A similar anti-tumour effect was also found following i.p. injection of BTNL2 mAb into CT26 (murine colonic adenocarcinoma) or A20 (murine B cell cancer) tumour-bearing mice (Fig. 1b, c). Here, DDX53 is linked to colon adenocarcinoma.